Combination of galectin inhibitor GCS-100 and BH3 mimetics eliminates both p53 wild type and p53 null AML cells

Galectin 3 (LGALS3) expression is prognostic for poor survival in acute myeloid leukemia (AML) patients. GCS-100 is a novel galectin inhibitor that may prove useful for AML therapy. In this study, we found GCS-100 induced apoptosis in AML cells. The agent reduced MCL-1 expression suggesting GCS-100...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Izdano u:Biochim Biophys Acta
Glavni autori: Ruvolo, Peter P., Ruvolo, Vivian R., Benton, Christopher B., AlRawi, Ahmed, Burks, Jared K., Schober, Wendy, Rolke, James, Tidmarsh, George, Hail, Numsen, Davis, R. Eric, Andreeff, Michael
Format: Artigo
Jezik:Inglês
Izdano: 2015
Teme:
Article
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC4775369/
https://ncbi.nlm.nih.gov/pubmed/26704388
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.bbamcr.2015.12.008
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items